Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 7/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | TBXAS1 | P24557 | 12/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12444490 | 0.94 | CYP1A2 (0.73) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL12329706 | 0.86 | TBXA2R (0.67) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL12444446 | 0.86 | TBXA2R (0.67) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL10350317 | 0.86 | CYP1A2 (0.72) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL12330318 | 0.86 | TBXA2R (0.67) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL10350639 | 0.86 | TBXA2R (0.67) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL13252899 | 0.86 | TBXA2R (0.82) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL10401494 | 0.84 | TBXA2R (0.68) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL10474732 | 0.84 | TBXA2R (0.65) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL12675684 | 0.84 | CYP1A2 (0.89) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150158838-A1 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses | EVOLVA SA (CH) | 2015-06-11 | — | — | US | disclosed |
| US-8952053-B2 | Prodrugs of substituted 1,3-dioxanes and their uses | EVOLVA SA (CH) | 2015-02-10 | — | — | US | disclosed |
| US-20130253045-A1 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses | EVOLVA SA (CH) | 2013-09-26 | — | — | US | disclosed |
| US-20130197030-A1 | Substituted 1,3-Dioxanes and There Uses | EVOLVA SA (CH) | 2013-08-01 | — | — | US | disclosed |
| US-8486994-B2 | Prodrugs of substituted 1,3-dioxanes and their uses | EVOLVA SA (CH) | 2013-07-16 | — | — | US | disclosed |
| US-20120252836-A1 | 1,3-Dioxanes and Their Uses | EVOLVA SA (CH) | 2012-10-04 | — | — | US | disclosed |
| US-20120142766-A1 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20100273824-A1 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2010-10-28 | — | — | US | disclosed |
| US-20100087517-A1 | PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087517-A1 | PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES | TBXA2R, PPARG, PPARA | TBXA2R 1/4885CYP1A2 37/4885CYP3A4 199/4885 |
| US-20120142766-A1 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES | TBXA2R, PPARG, PPARA | TBXA2R 1/4885CYP1A2 96/4885CYP3A4 434/4885 |
| US-20130197030-A1 | Substituted 1,3-Dioxanes and There Uses | TBXA2R, PPARG, PPARA | TBXA2R 1/4885CYP1A2 92/4885CYP3A4 426/4885 |
| US-20100273824-A1 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES | TBXA2R, PPARG, PPARA | TBXA2R 1/4885CYP1A2 96/4885CYP3A4 434/4885 |
| US-20120252836-A1 | 1,3-Dioxanes and Their Uses | TBXA2R, PPARG, PPARA | TBXA2R 1/4885CYP1A2 112/4885CYP3A4 505/4885 |
| US-20130253045-A1 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses | TBXA2R, PPARG, PPARA | TBXA2R 1/4885CYP1A2 37/4885CYP3A4 199/4885 |
| US-20150158838-A1 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses | TBXA2R, PPARG, PPARA | TBXA2R 1/4885CYP1A2 37/4885CYP3A4 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.